Evidence map›Paper›PMID 35134266›Full record

ArticleAsia-Pacific journal of clinical oncology2022

Managing advanced prostate cancer in the Asia Pacific region: "Real-world" application of Advanced Prostate Cancer Consensus Conference 2019 statements.

Edmund Chiong, Declan G Murphy, Nicholas C Buchan, Melvin L K Chua, Lukman Hakim, Agus Rizal Hamid, Sung K Hong, Lisa G Horvath, Ravi Kanesvaran, Makarand Khochikar and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asia-Pacific journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Edmund ChiongDepartment of Urology, National University Hospital, National University Health System, Singapore.
Declan G MurphyDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Nicholas C BuchanDepartment of Urology, Christchurch Hospital, Christchurch, New Zealand.
Melvin L K ChuaDivisions of Radiation Oncology and Medical Sciences, National Cancer Centre Singapore, Singapore.ORCID https://orcid.org/0000-0002-1648-1473
Lukman HakimDepartment of Urology, Faculty of Medicine, Airlangga University/Airlangga University Hospital, Surabaya, Indonesia.
Agus Rizal HamidDepartment of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Sung K HongDepartment of Urology, Seoul National University Bundang Hospital, Seongnam-si, Korea.
Lisa G HorvathDepartment of Medical Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
Ravi KanesvaranOncology Academic Programme, Duke-NUS Medical School, Singapore.
Makarand KhochikarDepartment of Uro-oncology, Siddhi Vinayak Ganapati Cancer Hospital, Miraj, India.
Jason LetranSection of Urology, Chinese General Hospital and Medical Center, Manila, Philippines.
Bannakij LojanapiwatDivision of Urology, Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Rohan MalekDepartment of Urology, Selayang Hospital, Kuala Lumpur, Malaysia.
Anthony C F NgSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
Nguyễn Tuấn VinhDepartment of Urology, Binh dan Hospital, Ho Chi Minh City, Vietnam.
See-Tong PangDepartment of Urology, Chang Gung Memorial Hospital Linkou, Taoyuan, Taiwan.
Darren M C PoonDepartment of Clinical Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong.
Teng Aik OngDivision of Urology, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Marniza SaadDepartment of Clinical Oncology, University of Malaya Medical Centre, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Kathryn SchubachMen's Health Melbourne, Melbourne, Victoria, Australia.
Ryoichi ShirokiDepartment of Urology, Fujita Health University, Nagoya, Japan.
Levent TürkeriDepartment of Urology, Acıbadem M.A. Aydınlar University, Istanbul, Turkey.
Scott WilliamsDivision of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Alvin WongDepartment of Haematology Oncology, National University Hospital, Singapore.
Dingwei YeDepartment of Urology, Shanghai Cancer Center, Shanghai, China.
ANZUP Cancer Trials GroupANZUP Cancer Trials Group, Sydney, New South Wales, Australia.
Ian D DavisANZUP Cancer Trials Group, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-9066-8244

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe second Asia-Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2020) gathered insights into the real-world application in the Asia-Pacific (APAC) region of consensus statements from the 3rd Advanced Prostate Cancer Consensus Conference (APCCC 2019).

methodsThe 4-h our virtual meeting in October 2020 brought together 26 experts from 14 APAC countries to discuss APCCC 2019 recommendations. Presentations were prerecorded and viewed prior to the meeting. A postmeeting survey gathered views on current practice.

resultsThe meeting and survey highlighted several developments since APAC APCCC 2018. Increased access and use in the region of PSMA PET/CT imaging is providing additional diagnostic and staging information for advanced prostate cancer and influencing local and systemic therapy choices. Awareness of oligometastatic disease, although not clearly defined, is increasing. Novel androgen receptor pathway antagonists are expanding treatment options. Cost and access to contemporary treatments and technologies continue to be a significant factor influencing therapeutic decisions in the region. With treatment options increasing, multidisciplinary treatment planning, shared decision making, and informed choice remain critical. A discussion on the COVID-19 pandemic highlighted challenges for diagnosis, treatment, and clinical trials and new service delivery models that will continue beyond the pandemic.

conclusionAPAC-specific prostate cancer research and data are important to ensure that treatment guidelines and recommendations reflect local populations and resources. Facilitated approaches to collaboration across the region such as that achieved through APAC APCCC meetings continue to be a valuable mechanism to ensure the relevance of consensus guidelines within the region.

Indexed as

COVID-19Prostatic NeoplasmsAsiaConsensus Statements as TopicHumansMalePandemicsPositron Emission Tomography Computed TomographyAsia-Pacificconsensusguidelinemetastasisprostate cancer

Identifiers

PMID35134266
PMCPMC9790439

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.